리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 06월
페이지 정보:영문 471 Pages
라이선스 & 가격 (부가세 별도)
한글목차
군발두통 세계 시장은 2030년까지 5억 6,040만 달러에 이를 전망
2024년에 4억 970만 달러로 추정되는 군발두통 세계 시장은 2024-2030년 CAGR 5.4%로 성장하여 2030년에는 5억 6,040만 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 Episodic는 CAGR 6.3%를 나타내고, 분석 기간 종료시에는 3억 7,970만 달러에 이를 것으로 예측됩니다. 만성 부문의 성장률은 분석 기간중 CAGR 3.6%로 추정됩니다.
미국 시장은 1억 1,160만 달러로 추정, 중국은 CAGR 8.7%로 성장 예측
미국의 군발두통 시장은 2024년에 1억 1,160만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 1억 1,330만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 8.7%로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 2.5%와 5.4%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 3.5%로 추정됩니다.
세계의 군발두통 시장 - 주요 동향과 촉진요인 정리
군발두통 관리가 신경과, 만성통증치료, 삶의 질 중재에서 중요성이 커지는 이유는?
군발성 두통은 그 격렬함 때문에 흔히 '자살 두통'이라고 불리며, 삶의 질과 생산성을 심각하게 저하시키는 쇠약성 신경질환으로 의학적으로나 연구적으로 많은 관심을 받고 있습니다. 군발두통은 한쪽의 심한 통증, 전형적으로 눈 주위의 통증, 주기적인 패턴으로 발생하는 것이 특징이며, 가장 견디기 힘든 1차성 두통 질환 중 하나입니다. 편두통에 비해 상대적으로 드물지만, 군발두통의 만성적 또는 반복적인 특성과 보편적으로 효과적인 치료법의 부족으로 인해 보다 전문적인 진단 및 치료 접근법이 요구되고 있습니다.
임상의와 환자들 사이에서 인지도가 높아짐에 따라 군발두통 시장은 효과적이고 즉각적인 완화, 장기적인 관리 옵션, 신경과 전문의가 주도하는 치료에 대한 광범위한 접근에 대한 긴급한 요구로 인해 형성되고 있습니다. 특히 다른 두통 유형과의 오진이 적시에 치료를 받는 데 있어 가장 큰 장벽으로 작용하고 있습니다.
군발두통 치료는 치료방법, 치료기전, 환자중심의 접근으로 어떻게 발전하고 있는가?
현재 군발두통의 관리 전략은 급성기 완화, 재발 방지, 발작 빈도 감소에 초점을 맞추었습니다. 급성 발작에 대한 1차적 치료는 고농도 산소 요법과 발작의 신속한 중단을 위한 속효성 트립탄계 약물(특히 피하 또는 비강 점적)입니다. 예방 요법으로는 부신피질 스테로이드, 리튬, 난치성 환자의 경우 CGRP 표적 생물학적 제제와 함께 벨라파밀이 여전히 일반적으로 처방되고 있습니다.
자동주사기, 비강주사제 등 약물 전달의 발전으로 투여 속도와 편의성이 개선되고 있으며, 이는 군발성 두통의 급속한 발병에 대처하는 데 중요한 요소입니다. 신경조절요법(비침습적 미주신경 자극 등) 및 단일클론항체 연구도 진행 중이며, 군발두통을 포함한 광범위한 두통 스펙트럼을 관리하기 위해 고안되었습니다.
이와 함께, 두통 추적 앱과 원격 신경과 진료와 같은 디지털 건강 도구는 환자의 참여와 증상 모니터링을 지원하여 보다 개인화된 치료 요법을 가능하게 하고, 치료 조정 시간을 단축하고 있습니다. 약물 개발자들은 단발성 군발두통과 장기적인 만성 군발두통 모두에 대한 임상시험 활동을 활발히 진행하고 있습니다.
군발두통 치료의 보급에 영향을 미치는 보건의료 환경과 지역 동향은?
군발성 두통 환자는 일반적으로 신경과 클리닉, 두통 전문센터, 3차 의료기관에서 관리되며, 영상 진단 및 감별 진단 프로토콜을 통해 이차적인 두통의 원인을 배제하는 데 도움이 됩니다. 일반 개업의와 응급실도 급성기 치료와 의뢰 경로에서 역할을 담당하고 있으며, 특히 진단이 부족한 지역에서는 더욱 그렇습니다.
북미와 유럽은 높은 진단율, 전문의에 의한 치료, 새로운 약리학적 치료와 비약리학적 치료를 받을 수 있다는 점에서 가장 큰 시장입니다. 아시아태평양은 아직 신흥 시장이지만, 특히 신경학 인프라가 구축되고 있는 도시지역에서 인지도가 높아지고 있습니다. 라틴아메리카, 중동 및 아프리카에서는 진단과 치료가 아직 제한적이지만, 공중보건 교육 및 옹호 활동을 통해 질환에 대한 인식이 점차 개선되고 있습니다.
군발두통 시장의 성장 요인은 무엇인가?
군발성 두통 치료제 시장은 임상적 인식이 개선되고, 신속한 증상 완화 및 장기적 관리에 대한 미충족 수요가 여전히 높기 때문에 시장이 확대되고 있습니다. 군발두통은 쇠약해지기 쉽고 만성적이거나 반복적으로 재발하기 때문에 환자나 신경학적 QOL을 중시하는 의료 시스템 모두에게 효과적인 치료가 우선순위가 되고 있습니다.
주요 성장 촉진요인으로는 두통에 특화된 약물 제제의 발전, 신경과 서비스 확대, 임상시험 활동 증가, 비침습적 치료 옵션에 대한 수요 증가 등을 들 수 있습니다. 환자 옹호, 두통의 병태생리에 대한 이해 확대, 디지털 헬스 플랫폼의 도입도 조기 개입과 지속적인 치료에 기여하고 있습니다.
세계적으로 신경질환의 부담이 증가하고 있는 가운데, 군발두통 치료는 개인 맞춤형 정밀 가이드를 통한 통증 관리 전략의 새로운 지평을 열 수 있을까?
부문
유형(episodic, chronic);약제 유형(즉효약, 장기 투여약, 단기 투여약);투여 경로(경구, 국소, 정맥내, 기타 투여 경로);판매채널(병원 약국, 소매 약국, 온라인 약국)
조사 대상 기업 예(총 42개사)
AbbVie Inc.
Allergan(a subsidiary of AbbVie)
Amgen Inc.
AstraZeneca
Bausch Health Companies Inc.
BetterLife Pharma Inc.
Ceruvia Lifesciences
Clexio Biosciences
Dr. Reddy's Laboratories Ltd.
ElectroCore, Inc.
Eli Lilly and Company
GlaxoSmithKline plc
Hikma Pharmaceuticals PLC
Johnson & Johnson Services, Inc.
Lundbeck Seattle BioPharmaceuticals
Lupin Limited
Novartis AG
Perrigo Company plc
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
AI 통합
당사는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트(UAE)
기타 중동
아프리카
제4장 경쟁
LSH
영문 목차
영문목차
Global Cluster Headache Market to Reach US$560.4 Million by 2030
The global market for Cluster Headache estimated at US$409.7 Million in the year 2024, is expected to reach US$560.4 Million by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Episodic, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$379.7 Million by the end of the analysis period. Growth in the Chronic segment is estimated at 3.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$111.6 Million While China is Forecast to Grow at 8.7% CAGR
The Cluster Headache market in the U.S. is estimated at US$111.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$113.3 Million by the year 2030 trailing a CAGR of 8.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.
Global Cluster Headache Market - Key Trends & Drivers Summarized
Why Is Cluster Headache Management Gaining Importance in Neurology, Chronic Pain Therapy, and Quality of Life Interventions?
Cluster headache-often termed “suicide headache” due to its extreme intensity-is gaining medical and research attention as a debilitating neurological disorder that significantly impairs quality of life and productivity. Characterized by severe unilateral pain, typically around the eye, and occurring in cyclical patterns, cluster headaches are among the most excruciating primary headache disorders. Though relatively rare compared to migraine, the chronic or episodic nature of cluster headaches and the lack of universally effective treatments are driving demand for more specialized diagnostic and therapeutic approaches.
As awareness grows among clinicians and patients alike, the cluster headache market is being shaped by an urgent need for effective, fast-acting relief, long-term management options, and broader access to neurologist-guided care. Improved recognition of the condition is leading to earlier diagnosis and targeted intervention, particularly as misdiagnosis with other headache types remains a common barrier to timely treatment.
How Are Therapeutic Modalities, Delivery Mechanisms, and Patient-Centric Approaches Advancing Cluster Headache Treatment?
Current management strategies for cluster headache focus on acute relief, prevention of recurrence, and reduction of attack frequency. First-line treatments for acute episodes include high-flow oxygen therapy and fast-acting triptans (particularly subcutaneous or nasal formulations) to abort attacks quickly. For preventive therapy, verapamil remains a commonly prescribed agent, alongside corticosteroids, lithium, and CGRP-targeting biologics in refractory cases.
Advances in drug delivery mechanisms-such as auto-injectors and intranasal sprays-are improving speed and ease of administration, critical factors in managing the rapid onset of cluster episodes. Research is also underway into neuromodulation therapies (e.g., non-invasive vagus nerve stimulation) and monoclonal antibodies designed for broader headache spectrum management, including cluster headache.
In parallel, digital health tools such as headache tracking apps and remote neurology consultations are supporting patient engagement and symptom monitoring, enabling more personalized treatment regimens and reducing time to therapeutic adjustment. Clinical trial activity is increasing as drug developers target both short-cycle episodic cluster headaches and long-term chronic forms.
Which Healthcare Settings and Regional Trends Are Influencing Cluster Headache Treatment Uptake?
Cluster headache patients are typically managed in neurology clinics, headache specialty centers, and tertiary care hospitals where imaging and differential diagnosis protocols help rule out secondary headache causes. General practitioners and emergency departments also play a role in acute care and referral pathways, particularly in underdiagnosed regions.
North America and Europe represent the largest markets due to higher diagnosis rates, availability of specialist care, and access to newer pharmacologic and non-pharmacologic treatments. Asia-Pacific, while still emerging, is witnessing increased awareness, particularly in urban centers with growing neurology infrastructure. In Latin America, the Middle East, and Africa, diagnosis and treatment remain limited, but public health education and advocacy efforts are gradually improving condition recognition.
What Are the Factors Driving Growth in the Cluster Headache Market?
The market for cluster headache therapeutics is growing as clinical awareness improves and unmet needs in rapid symptom relief and long-term management remain high. The debilitating nature of the disorder, combined with its chronic or recurrent episodes, makes effective treatment a priority for both patients and healthcare systems focused on neurological quality of life.
Key growth drivers include advancements in headache-specific drug formulations, expansion of neurology services, increased clinical trial activity, and rising demand for non-invasive treatment options. Patient advocacy, greater understanding of headache pathophysiology, and the introduction of digital health platforms are also contributing to early intervention and sustained care.
As the burden of neurological disorders escalates globally, could cluster headache therapies become a new frontier in personalized, precision-guided pain management strategies?
SCOPE OF STUDY:
The report analyzes the Cluster Headache market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Episodic, Chronic); Drug Type (Fast-Acting Drugs, Long-Term Drugs, Short-Term Drugs); Administration Route (Oral, Topical, Intravenous, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 42 Featured) -
AbbVie Inc.
Allergan (a subsidiary of AbbVie)
Amgen Inc.
AstraZeneca
Bausch Health Companies Inc.
BetterLife Pharma Inc.
Ceruvia Lifesciences
Clexio Biosciences
Dr. Reddy's Laboratories Ltd.
ElectroCore, Inc.
Eli Lilly and Company
GlaxoSmithKline plc
Hikma Pharmaceuticals PLC
Johnson & Johnson Services, Inc.
Lundbeck Seattle BioPharmaceuticals
Lupin Limited
Novartis AG
Perrigo Company plc
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Cluster Headache - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Diagnosis of Trigeminal Autonomic Cephalalgias Throws the Spotlight on Cluster Headache Management
Growth in Awareness of Chronic and Episodic Cluster Headaches Spurs Demand for Acute and Preventive Therapies
Development of Targeted Treatments Including CGRP Antagonists and Sphenopalatine Ganglion Blocks Enhances Relief Options
Expansion of Portable Oxygen Therapy Devices and Neuromodulation Tools Supports Home-Based Symptom Control
Use of Lithium, Verapamil, and Galcanezumab in Off-Label and On-Label Protocols Broadens Clinical Management Approaches
Integration With Digital Headache Diaries and Wearables Supports Trigger Monitoring and Pattern Analysis
Growth in Dedicated Headache Clinics and Neurology Teleconsultations Improves Timely Access to Care
Focus on Early Intervention During Cluster Periods Enhances Patient Quality of Life and Work Functionality
Patient Advocacy and Awareness Campaigns Promote Faster Diagnosis and Insurance Coverage for Treatment
Recognition of Cluster Headache as a Neurological Disability Supports Policy and Research Funding
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Cluster Headache Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Cluster Headache by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Cluster Headache by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Cluster Headache by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Episodic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Episodic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Episodic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Chronic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Chronic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Chronic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Fast-Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Fast-Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Fast-Acting Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Long-Term Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Long-Term Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Long-Term Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Short-Term Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Short-Term Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Short-Term Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 31: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 34: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 37: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 39: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 40: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 41: USA Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 42: USA Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 43: USA 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: USA Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 46: USA 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 47: USA Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 48: USA Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 49: USA 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 50: USA Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: USA Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 52: USA 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
CANADA
TABLE 53: Canada Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 55: Canada 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 56: Canada Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: Canada Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 58: Canada 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 59: Canada Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 60: Canada Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 61: Canada 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 62: Canada Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: Canada Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 64: Canada 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
JAPAN
Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 65: Japan Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: Japan Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 67: Japan 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 68: Japan Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: Japan Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 70: Japan 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 71: Japan Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 72: Japan Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 73: Japan 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 74: Japan Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: Japan Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 76: Japan 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
CHINA
Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 77: China Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 78: China Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 79: China 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 80: China Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: China Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 82: China 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 83: China Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: China Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 85: China 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 86: China Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: China Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 88: China 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
EUROPE
Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 89: Europe Recent Past, Current & Future Analysis for Cluster Headache by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 90: Europe Historic Review for Cluster Headache by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 91: Europe 15-Year Perspective for Cluster Headache by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 92: Europe Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: Europe Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 94: Europe 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 95: Europe Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 96: Europe Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 97: Europe 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 98: Europe Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: Europe Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 100: Europe 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 101: Europe Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 102: Europe Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 103: Europe 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
FRANCE
Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 104: France Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: France Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 106: France 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 107: France Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: France Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 109: France 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 110: France Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: France Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 112: France 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 113: France Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: France Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 115: France 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
GERMANY
Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 116: Germany Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: Germany Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 118: Germany 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 119: Germany Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 120: Germany Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 121: Germany 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 122: Germany Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: Germany Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 124: Germany 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 125: Germany Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 126: Germany Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 127: Germany 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
ITALY
TABLE 128: Italy Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: Italy Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 130: Italy 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 131: Italy Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 132: Italy Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 133: Italy 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 134: Italy Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 135: Italy Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 136: Italy 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 137: Italy Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 138: Italy Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 139: Italy 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
UNITED KINGDOM
Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 140: UK Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 141: UK Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 142: UK 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 143: UK Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 144: UK Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 145: UK 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 146: UK Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 147: UK Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 148: UK 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 149: UK Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 150: UK Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 151: UK 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
SPAIN
TABLE 152: Spain Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 153: Spain Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 154: Spain 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 155: Spain Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 156: Spain Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 157: Spain 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 158: Spain Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 159: Spain Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 160: Spain 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 161: Spain Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 162: Spain Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 163: Spain 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
RUSSIA
TABLE 164: Russia Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 165: Russia Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 166: Russia 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 167: Russia Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 168: Russia Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 169: Russia 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 170: Russia Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 171: Russia Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 172: Russia 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 173: Russia Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 174: Russia Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 175: Russia 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 177: Rest of Europe Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 178: Rest of Europe 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 180: Rest of Europe Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 181: Rest of Europe 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 183: Rest of Europe Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 184: Rest of Europe 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 186: Rest of Europe Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 187: Rest of Europe 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 189: Asia-Pacific Historic Review for Cluster Headache by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 190: Asia-Pacific 15-Year Perspective for Cluster Headache by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 192: Asia-Pacific Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 193: Asia-Pacific 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 195: Asia-Pacific Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 196: Asia-Pacific 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 198: Asia-Pacific Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 199: Asia-Pacific 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 201: Asia-Pacific Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 202: Asia-Pacific 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
AUSTRALIA
Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 203: Australia Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 204: Australia Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 205: Australia 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 206: Australia Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 207: Australia Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 208: Australia 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 209: Australia Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 210: Australia Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 211: Australia 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 212: Australia Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 213: Australia Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 214: Australia 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
INDIA
Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 215: India Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 216: India Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 217: India 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 218: India Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 219: India Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 220: India 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 221: India Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 222: India Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 223: India 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 224: India Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 225: India Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 226: India 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 227: South Korea Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 228: South Korea Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 229: South Korea 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 230: South Korea Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 231: South Korea Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 232: South Korea 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 233: South Korea Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 234: South Korea Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 235: South Korea 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 236: South Korea Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 237: South Korea Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 238: South Korea 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 240: Rest of Asia-Pacific Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 243: Rest of Asia-Pacific Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 246: Rest of Asia-Pacific Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 249: Rest of Asia-Pacific Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
LATIN AMERICA
Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 251: Latin America Recent Past, Current & Future Analysis for Cluster Headache by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 252: Latin America Historic Review for Cluster Headache by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 253: Latin America 15-Year Perspective for Cluster Headache by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 254: Latin America Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 255: Latin America Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 256: Latin America 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 257: Latin America Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 258: Latin America Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 259: Latin America 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 260: Latin America Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 261: Latin America Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 262: Latin America 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 263: Latin America Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 264: Latin America Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 265: Latin America 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 266: Argentina Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 267: Argentina Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 268: Argentina 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 269: Argentina Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 270: Argentina Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 271: Argentina 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 272: Argentina Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 273: Argentina Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 274: Argentina 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 275: Argentina Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 276: Argentina Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 277: Argentina 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
BRAZIL
TABLE 278: Brazil Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 279: Brazil Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 280: Brazil 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 281: Brazil Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 282: Brazil Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 283: Brazil 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 284: Brazil Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 285: Brazil Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 286: Brazil 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 287: Brazil Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 288: Brazil Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 289: Brazil 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
MEXICO
TABLE 290: Mexico Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 291: Mexico Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 292: Mexico 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 293: Mexico Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 294: Mexico Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 295: Mexico 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 296: Mexico Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 297: Mexico Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 298: Mexico 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 299: Mexico Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 300: Mexico Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 301: Mexico 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 303: Rest of Latin America Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 304: Rest of Latin America 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 306: Rest of Latin America Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 307: Rest of Latin America 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 309: Rest of Latin America Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 310: Rest of Latin America 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 312: Rest of Latin America Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 313: Rest of Latin America 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
MIDDLE EAST
Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 314: Middle East Recent Past, Current & Future Analysis for Cluster Headache by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 315: Middle East Historic Review for Cluster Headache by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 316: Middle East 15-Year Perspective for Cluster Headache by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 317: Middle East Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 318: Middle East Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 319: Middle East 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 320: Middle East Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 321: Middle East Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 322: Middle East 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 323: Middle East Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 324: Middle East Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 325: Middle East 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 326: Middle East Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 327: Middle East Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 328: Middle East 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
IRAN
TABLE 329: Iran Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 330: Iran Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 331: Iran 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 332: Iran Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 333: Iran Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 334: Iran 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 335: Iran Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 336: Iran Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 337: Iran 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 338: Iran Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 339: Iran Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 340: Iran 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
ISRAEL
TABLE 341: Israel Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 342: Israel Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 343: Israel 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 344: Israel Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 345: Israel Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 346: Israel 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 347: Israel Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 348: Israel Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 349: Israel 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 350: Israel Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 351: Israel Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 352: Israel 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 354: Saudi Arabia Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 355: Saudi Arabia 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 357: Saudi Arabia Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 358: Saudi Arabia 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 360: Saudi Arabia Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 361: Saudi Arabia 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 363: Saudi Arabia Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 364: Saudi Arabia 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 365: UAE Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 366: UAE Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 367: UAE 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 368: UAE Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 369: UAE Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 370: UAE 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 371: UAE Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 372: UAE Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 373: UAE 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 374: UAE Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 375: UAE Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 376: UAE 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 378: Rest of Middle East Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 379: Rest of Middle East 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 381: Rest of Middle East Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 382: Rest of Middle East 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 384: Rest of Middle East Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 385: Rest of Middle East 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 387: Rest of Middle East Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 388: Rest of Middle East 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
AFRICA
Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 389: Africa Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 390: Africa Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 391: Africa 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
TABLE 392: Africa Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 393: Africa Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 394: Africa 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 395: Africa Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 396: Africa Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 397: Africa 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
TABLE 398: Africa Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 399: Africa Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 400: Africa 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030